Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

Completed · Phase 4

Conditions studied: Cataract

In brief

To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.

Key facts

Study ID

NCT00870103

Run by

Alcon Research

People needed

64

Starts

2008-09-01

Last updated by the study team

2010-03-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≧18 years of age
• able to sign an informed consent and complete all required visits
• intends to have a cataract extraction surgery followed by implantation of a posterior chamber Intraocular lens (IOL)
• Intraocular Pressure (IOP) ≦ 20 millimeters mercury (mmHg)

You may not qualify if…

• Uncontrolled glaucoma or IOP
• use of ocular anti-infectious during the study and within 30 days prior to the enrollment, secondary implantation or replacement of IOL in the study eye
• use of steroid during the study or within 14 days prior to enrollment

Where it is running

• Alcon Call Center — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.